AsymBio Completes its Dual-Site, One-Center Network with Fengxian Commercial Manufacturing Site Operational, Enhancing End-to-End Biologics CDMO Capabilities

Rhea-AI Summary

AsymBio (ASLTY) announced its Fengxian commercial manufacturing site in Shanghai is now operational, completing a three-site Shanghai "Golden Triangle" with Zhangjiang and Jinshan. The network delivers end-to-end biologics CDMO capabilities from early R&D to large-scale commercial manufacturing.

The Dual Sites + One Center model links technology, pilot-scale, and commercial production and integrates Tianjin payload–linker resources to support antibody, protein, ADC, and NDC programs with specified single-use bioreactors and conjugation reactors.

Positive

• Fengxian site operational completing Zhangjiang–Jinshan–Fengxian Shanghai network
• End-to-end CDMO coverage from early R&D through commercial supply
• Capacity scope includes single-use bioreactors 200L/500L/2,000L and conjugation reactors 50L–500L
• Integrated payload–linker linkage with Tianjin for end-to-end conjugate manufacturing

Negative

• None.

SHANGHAI, March 09, 2026 (GLOBE NEWSWIRE) -- AsymBio, a subsidiary of Asymchem Group (stock code: 002821.SZ /6821.HK), recently announced that its Fengxian commercial manufacturing site in Shanghai has officially commenced operations. This milestone completes a Shanghai-based “Golden Triangle” footprint comprising the Zhangjiang Science & Technology Center, Jinshan Site, and Fengxian Site. The three locations integrate end-to-end CDMO capabilities from early R&D and process development through clinical pilot-scale production, to commercial manufacturing, advancing client programs from IND to BLA through efficient cross-site coordination.

AsymBio’s “Dual Sites + One Center” model provides connected functions and complementary strengths across the biologics lifecycle:

• Zhangjiang Science & Technology Center: A technology-driven central engine for innovation, focusing on early R&D and process development for antibodies, proteins, novel drug conjugates (NDCs), and other advanced therapies, with forward-looking technology deployment. The Center builds and optimizes technology platforms for cell line development, upstream/downstream process development and optimization, conjugation toolbox development, and analytical method development. It supports concept-to-process translation and enables defined technology transfer pathways for subsequent pilot and commercial manufacturing.
• Jinshan Site: A one-stop manufacturing site providing manufacturing services from clinical supply and pilot-scale to commercial production, covering drug substance (DS) and drug product (DP) capabilities for antibodies, protein therapeutics, ADCs, and NDCs. The site supports programs across clinical stages, spanning from R&D to antibody DS/DP and conjugate DS/DP.
• Fengxian Site: A newly commissioned intelligent, large-scale, and internationally compliant manufacturing site focused on late-stage development and large-scale commercial supply for antibodies, protein therapeutics, ADCs, and NDCs. It introduces advanced smart manufacturing systems to enable compliant operations and meet global demand for large-scale supply of high-quality biologics.
  

Dual-site GMP manufacturing to flexibly support capacity needs from early pilot to large-scale commercial supply

The network is equipped with:

• Single-use bioreactors for antibody drug substance: 200 L / 500 L / 2,000 L
• Conjugation reactors for conjugate drug substance: 50 L / 100 L / 200 L / 500 L
• ORABS fully automated filling line
• Multi-specification lyophilization and isolator filling systems: 5 m² / 10 m² / 15 m² / 20 m² lyophilizers, supporting 2R–20R formats

These capabilities support diverse dosage forms and specifications and strengthen integrated delivery in biologics, enabling customized manufacturing services.

Integrating Asymchem’s Payload–Linker Facility to Provide End-to-End, One-Stop Services for Drug Conjugates

AsymBio integrates Asymchem Group resources by linking Shanghai’s conjugation manufacturing with the Group’s Tianjin payload–linker R&D and manufacturing capabilities. The Tianjin site focuses on payload–linker process development and manufacturing while connecting seamlessly with Shanghai's antibody DS, conjugate DS, and DP manufacturing and fill-finish. This end-to-end model enables cross-regional coordination, ensures supply chain stability, and improves both execution efficiency and cross-stage collaboration.

With the Fengxian site now in operation, AsymBio’s Shanghai footprint covers the full value chain from early-stage development through commercialization. Through the “Dual Sites + One Center” model and integrated payload–linker capabilities, the company provides global clients with efficient, reliable, and customized development and manufacturing solutions, supporting pipelines from the laboratory to clinical development and commercialization.

About AsymBio

AsymBio, a subsidiary of Asymchem Group, focuses exclusively on biopharmaceutical CDMO services. With more than 25 years of experience and global operations, the company delivers one-stop CDMO services from early-stage and process development to clinical, toxicology, and commercial-scale manufacturing. Building on deep ADC experience, AsymBio is expanding into NDCs, including RDCs, AOCs, PDCs, APCs, BsADCs, and dpADCs, while maintaining comprehensive service capabilities for antibody therapeutics (monoclonal, bispecific, and multispecific antibodies) and protein-based therapeutics (fusion proteins, recombinant proteins).

For more information, visit www.asymbio.com or follow us on LinkedIn.

Business inquiries: MKT@asymchem.com.cn

Compliance Notes

Forward-Looking Statement Disclaimer: This press release contains forward-looking statements regarding future events and expectations. Actual results may differ materially due to various factors. AsymBio undertakes no obligation to update these statements.

Non-Solicitation Statement: This announcement is for informational purposes only and does not constitute investment advice or an offer to buy or sell securities.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8ed786fe-4826-4980-b706-9d97a67cfb51

FAQ

What does AsymBio's Fengxian site opening mean for ASLTY capacity?

It expands ASLTY commercial capacity by adding a large-scale, intelligent manufacturing site for late-stage supply. According to the company, Fengxian supports antibody and conjugate commercial production and integrates with existing Zhangjiang and Jinshan capabilities for cross-site supply flexibility.

How does ASLTY's Dual Sites + One Center model support biologics development?

It connects early R&D, pilot-scale, and commercial manufacturing across three Shanghai sites for streamlined development. According to the company, the model enables defined technology transfer pathways and coordinated execution from IND through potential BLA submissions.

What specific manufacturing equipment does ASLTY report at its Shanghai network?

The Shanghai network includes single-use bioreactors (200L/500L/2,000L), conjugation reactors (50L/100L/200L/500L) and ORABS filling lines. According to the company, multi-specification lyophilizers and isolator filling systems support diverse 2R–20R formats.

How does the Tianjin payload–linker integration affect ASLTY's services?

Integration enables end-to-end conjugate manufacturing by combining Tianjin payload–linker R&D and manufacturing with Shanghai conjugation and fill-finish. According to the company, this cross-regional linkage is intended to improve supply chain stability and execution efficiency.

Which modalities can ASLTY support across its Shanghai sites after Fengxian began operations?

ASLTY can support antibodies, protein therapeutics, ADCs, and novel drug conjugates (NDCs) across development stages. According to the company, the combined sites cover cell line work, upstream/downstream process development, conjugation, analytical methods, and commercial fill-finish.